We assessed the laboratory performance and clinical utility of a new commercial third-generation assay of thyroidstimulating hormone (TSH), Amerlite TSH-30. The interassay CV was 6% at TSH concentrations of -0.08 mlU/L, and the analytical and functional detection limitsof the assay were 0. 005 
samples were significantly lower than those found by using two other TSH assays; bias data obtained from thyroliberin stimulation tests suggested that the negative bias found with TSH-30 may be due to the heterogeneity of TSH in basal samples. TSH-30 completely discriminated hyperthyroid and hypothyroid patients from euthyroid ambulatory patients but also detected TSH (>0.0125 mlU/L) in 3 of 46 untreated hyperthyroid patients. Com (4) (5) (6) . Measurement of thyroid hormone concentrations was required only in patients with undetectable or above-normal TSH, to distinguish between subclinical and overt thyroid disease. The introduction of the IMAs has also provided a simple and effective method to monitor the adequacy of thyroxine replacement therapy (7) (8) (9) .
With further experience, however, it became apparent that some euthyroid hospitalized patients had subnormal (<0.1 mIU/L) TSH concentrations and, indeed, in such a population subnormal TSH was more often due to nonthyroidal illness or to overreplacement with thyroxine than to hyperthyroidism (6, [10] [11] [12] [13] 
Materials and Methods

Patients
Analytical recovery.
We assessed the recovery of TSH on three separate occasions, using serum taken from three euthyroid subjects to which had been added TSH 
Results
Analytical Evaluation
Precision and sensitivity.
The precision data are shown in Table 2 (Figure 2 ).
InterferinglgMantibody.
In each of the eight samples known to contain 1gM antibody that interfered with TSH-Fast, the TSH-Simu1TRAC results were significantly lower than the TSH-Fast results ( values. In the euthyroid patients (n = 185), TSH-30 (y) produced results -23% lower than TSH-Fast (x) results (y = 0.77x -0.1; r = 094; P <0.0001) and 39% lower than TSH-Simul-TRAC (x') results (y = 0.61x' -0.1; r = 0.95; P <0.0001). In the hypothyroid patients (n = 50), the negative bias 
Patients'Data
The following results for patients' sera are illustrated in Figure 3 .
Euthyroid patients. Reference ranges derived from the euthyroid patients (95% confidence limits of untransformed data) were 0.24 to 4.2 mIUfL for TSH-Faat and 0.14 to 3.5 mIU/L for TSH-30. These reference ranges reflect the differences in bias found for the two methods. being significantly above the reference range (Figure 4) . Nonthyroidal illness. Each of the six clinically euthymid patients with nonthyroidal ifiness whose TSH-Simu1TRAC results were high had increased concentrations of TSH by both TSH-Fast and TSH-30. All nine patients with TSH-Simu1TRAC <0.1 mIU/L had TSH concentrations by TSH-Fast and TSH-30 that were also <0.1 mIUIL. Details of these patients are listed in Table  6 . In general, these were elderly patients but no common illness was apparent. A 10th patient had TSH <0.1 mJIJ/L by TSH-30, but this was a result of the negative bias of the TSH-30 in comparison with the TSH-Fast assay because the TSH-Fast value was 0.12 mIIJ/L. In basal samples TSH values by TSH-30 were consistently lower than concentrations found with TSH-Fast and TSH-Simu1TBAC, and the differences in TSH values observed between these assays were considerable. replacement therapy. They and others suggested that "monitoring the serum TSH level to ascertain that it remains above the lower limit of the normal range will prevent the potential risk of over-treatment" (21), the risk being largely related to the possibility of inducing or exacerbating osteoporosis (22) (23) (24) . Now that the third-generation assays, induding TSH-30, are demonstrating that most thyroxinetreated patients with TSH <0.1 mIUIL by second-generation assay have clearly detectable TSH concentrations in the third-generation assay, it will be important to determine whether only the few patients with undetectable TSH by third-generation assays are at increased risk from any adverse effects of overreplacement.
In conclusion, Amerlite TSH-30 is a rapid and precise third-generation assay that readily lends itself to automation with the Kodak Process Centre; we are at pre-sent evaluating the precision of the assay on this instrument. Amerlite TSH-30 provides improved but not complete discrimination between (a) patients with low TSH because of nonthyroidal illness and (or) thyroxine replacement therapy and (b) patients with low TSH caused by hyperthyroidism.
The speed of the assay is such that results can be provided to the clinician within 1 to 2 h of receipt of the patient's sample.
